

ASX RELEASE

The America Society of Breast Surgeons (ASBrS) releases official position statement on screening mammography

Wellington, NZ, 13th May 2019: [Volpara Health Technologies](#) ("Volpara"; ASX: VHT), a medical technology company whose AI imaging algorithms assist the early detection of breast cancer, has advised that last week the ASBrS released an official position statement on screening mammography where it makes recommendations regarding both how to assess breast cancer risk with breast density as an input and how to act upon such an assessment.

In its [press release](#) the ASBrS described the goal of the position statement: "... to summarise the data and to make clear recommendations regarding breast cancer screening for both women with average and higher risk, as well as to make surveillance imaging recommendations for women with a prior history of breast cancer. In addition, the role of the various screening modalities will be delineated for these risk groups."

The Volpara®Density™ clinical application is the most clinically validated automated breast density measurement tool available today. Further, it is the only commercial breast density measurement tool included in one of the most complete breast cancer risk models currently available, the Tyrer-Cuzick Risk Evaluation Tool, version 8. The ASBrS explicitly identifies Tyrer-Cuzick as a suitable model for use in risk assessment.

The ASBrS official position statement makes four recommendations:

- Women age >25 should undergo formal risk assessment for breast cancer;
- Women with an average risk of breast cancer should initiate yearly screening mammography at age 40;
- Women with a higher-than-average risk of breast cancer should undergo yearly screening mammography and be offered yearly supplemental imaging; this screening should be initiated at a risk-based age; and
- Screening mammography should cease when life expectancy is <10 years.

Dr Ralph Highnam, CEO of Volpara, said: "We have seen a large increase in activity and enquiries in the breast cancer risk space recently, and it is good to see that the ASBrS have put forward a position statement that very clearly outlines its recommended approach to breast cancer screening—an approach that, significantly, begins to personalise the risk-assessment experience for each woman based on her individual risk. It is also encouraging to see how important density is in that assessment and the vital role that Volpara can play in helping women receive the right care at the right age."

ENDS.

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparasolutions.com
t: +64 21 149 0541

Kyahn Williamson
WE Buchan
kwilliamson@we-buchan.com
t: +61 3 9866 4722

About Volpara Health Technologies Limited (ASX: VHT)

VHT is a MedTech SaaS company founded in 2009 on research originally conducted at Oxford University. VHT's clinical applications for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide software, Volpara®Enterprise™, provides role-specific dashboards and wide-ranging benchmarking analytics to help clinics manage their business more efficiently.

VHT's technology and services have been used by customers and/or research projects in 38 countries and are supported by numerous patents, trademarks and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$40 million, including A\$20 million in April and May 2018. VHT is based in Wellington, New Zealand.

For more information, visit www.volparasolutions.com